39 research outputs found
Supplemental Material, APC-18-0007_FINAL_Supplementary_file_1_(1) - The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation: The Johns Hopkins Pathology Experience
No full textSupplemental Material, APC-18-0007_FINAL_Supplementary_file_1_(1) for The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation: The Johns Hopkins Pathology Experience by Kathleen H. Burns, Michael J. Borowitz, Karen C. Carroll, Christopher D. Gocke, Jody E. Hooper, Timothy Amukele, Aaron A. R. Tobian, Allen Valentine, Rob Kahl, Vanessa Rodas-Eral, John K. Boitnott, J. Brooks Jackson, Fred Sanfilippo, and Ralph H. Hruban in Academic Pathology</p
Africa CDC: Establishing Integrated Surveillance and Laboratory Networks for Rapid Disease Detection and Response, Control, Prevention, and Clinical Care in Africa
No full textNo abstract available
69 Utilization and Diagnostic Yield of Paraneoplastic Panel Testing at an Academic Tertiary Care Facility
No full text
68 Creation and Evaluation of a Laboratory Administration Curriculum for Pathology Residents
No full textCreation and Evaluation of a Laboratory Administration Curriculum for Pathology Residents
No full textEssential Diagnostics for the Use of World Health Organization Essential Medicines
No full textAbstract
BACKGROUND
There are numerous barriers to achieving high-quality laboratory diagnostic testing in resource-limited countries. These include inconsistent supply chains, variable quality of diagnostic devices, lack of human and financial resources, the ever-growing list of available tests, and a historical reliance on syndromic treatment algorithms. A list of essential diagnostics based on an accepted standard like the WHO Essential Medicines List (EML) could coordinate stakeholders in the strengthening of laboratory capacity globally.
METHODS
To aid in the creation of an essential diagnostics list (EDL), we identified laboratory test indications from expert databases for the safe and effective use of WHO EML medicines. In all, 446 EML medicines were included in the study. We identified 279 conditions targeted by these medicines, spanning communicable and noncommunicable diseases (e.g., HIV, diabetes mellitus).
RESULTS
We found 325 unique diagnostic tests, across 2717 indications, associated with the identified conditions or their associated medicines. The indications were divided into 10 categories: toxicity (865), diagnosis (591), monitoring (379), dosing/safety (325), complications (217), pathophysiology (154), differential diagnosis (97), comorbidities (53), drug-susceptibility testing (22), and companion diagnostic testing (14). We also created a sublist of 74 higher-priority tests to help define the core of the EDL.
CONCLUSIONS
An EDL such as we describe here could align the global health community to solve the problems impeding equitable access to high-quality diagnostic testing in support of the global health agenda.
</jats:sec
